Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Special Report
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Authored by Jeffrey Neal Johnson. First Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1 trillion.
According to Jim Rickards, an announcement is expected around April 15 that could bring this historic discovery into public view. See the full details on this $2 gold stock before April 15
Abbott Laboratories’ stock price recently touched a 52-week low, briefly closing just above $100 in late March. This sharp downturn has left many wondering whether the foundation of this industry leader is cracking. A closer look at Abbott Laboratories’s situation suggests a potential disconnect between market sentiment and operational reality, raising an important question: Is the market’s pessimism justified, or has a significant value opportunity emerged for long-term investors? Separating the Signal From the NoiseA stock like Abbott doesn't fall without reason, and its recent decline stems from two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, primarily due to market-share losses in its U.S. pediatric business and pricing dynamics that constrained sales volume. Management has acknowledged the challenge and laid out a clear turnaround plan. CEO Robert B. Ford outlined price and promotion initiatives and a pipeline of at least eight new product launches in 2026 to reignite volume growth, forecasting a return to growth in the second half of the year. The second factor is external and broader in scope. The market has been undergoing a significant rotation of capital. During periods of economic optimism, investors often shift funds away from stable, defensive sectors like the healthcare sector and into higher-beta areas such as artificial intelligence (AI) and the energy sector in pursuit of faster returns. This broad market trend has pressured many fundamentally sound healthcare companies, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile the Nutrition segment navigates a short-term recovery, Abbott Laboratories' core remains robust, powered by its largest and most profitable division: Medical Devices. This segment is not just stable; it is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model provides a powerful counterbalance to the isolated weakness in Nutrition. The company's true strength is most evident in these high-performing areas.
Medical Devices: The medical devices business is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a growth phenomenon. The product line, which lets users track glucose levels without routine fingersticks, generated over $7.5 billion in sales in 2025 and is a primary driver of Abbott’s sustained success. Cardiovascular Leadership: Abbott is a dominant force in cardiovascular health. Its Electrophysiology business grew at a double-digit pace, while Structural Heart posted strong organic growth of 8.7%. This strength reflects a portfolio of best-in-class products, such as MitraClip and TriClip, which offer minimally invasive heart valve repair solutions, alongside a pipeline of innovations including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Beyond its current portfolio, Abbott is taking strategic steps to secure future growth through the acquisition of Exact Sciences. Exact Sciences is a leader in cancer screening and diagnostics, best known for its non-invasive colon cancer test, Cologuard. The acquisition would position Abbott as a major player in the rapidly expanding, multi-billion-dollar market for cancer diagnostics, adding a new high-growth vertical that could contribute meaningfully to revenue for years to come. This bullish view is shared by professional analysts. Wall Street analysts maintain a Moderate Buy consensus rating on the stock. The average 12-month price target is $135.47, implying potential upside of over 30% from current levels and signaling a belief that the stock may be undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on reliable income, Abbott’s dividend is a key attraction. Abbott Laboratories is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That remarkable track record demonstrates a long-term commitment to returning capital to shareholders through all market cycles. The recent decline in Abbott’s stock price has a direct benefit for new investors: a higher dividend yield. At its current price, Abbott offers a dividend yield of approximately 2.5%, allowing investors to lock in a higher rate of income from this historically reliable payer. The dividend payout ratio is about 68% of reported earnings, and the dividend accounts for only 37% of its cash flow, indicating Abbott generates more than enough cash to cover payouts with room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott appears disconnected from the company's business reality. Temporary headwinds in a single division, combined with broad market rotations, have pushed the stock lower. Meanwhile, Abbott's fundamental growth engines are accelerating: its dominant Medical Devices division continues to deliver strong results, the dividend remains a bedrock of reliability, and strategic catalysts like the Exact Sciences deal sit on the horizon. For investors with a long-term perspective, the present valuation highlights a meaningful gap between price and intrinsic value that may warrant serious consideration. |
